Navigation Links
Tianyin Pharmaceutical to Present at the Brean Murray All-Cap All-China Conference in New York City on May 20, 2008 at 10:15 a.m. EDT

CHENGDU, China, May 12 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (OTC Bulletin Board: TYNP), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company will present at the Brean Murray All-Cap All-China Conference on Tuesday, May 20, 2008 at 10:15 a.m. EDT. The Conference will be held at the Waldorf Astoria, which is located in New York City.

The presentation will take place in the Sutton Suite and management will participate in meetings with analysts and investors throughout the day. Mr. Stewart Lor, a member of the Board of Directors, will present on the Company's behalf.

Management will discuss the Company's current product portfolio, development pipeline, research and development platform, recent financial highlights and its long-term growth strategy.

Participation is by invitation and registration is mandatory. For more information on the conference contact your Brean Murray representative or visit

About Brean Murray

Brean Murray, Carret & Co. was founded over 30 years ago and is a full-service, boutique investment bank dedicated to small cap and emerging growth companies and those who invest in them. As a research-driven securities firm, the firm is dedicated to delivering high quality investment banking services and investment ideas to its clients. The firms focuses on the following sectors: China Small Cap, Consumer Products and Retailing, Healthcare and Biotechnology, Resources and Technology.

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 34 modernized TCMs in the market, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance Program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 51 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 523 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 869 employees. Tianyin achieved revenue of $20.4 million and net income of $3.95 million in FY2007 ending June 30, 2007.

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact:

For the Company:

Allen Tang, Ph.D., MBA, Assistant to the CEO

China 15821225642


HC International, Inc.

Alan Sheinwald

US (914) 669-0222

SOURCE Tianyin Pharmaceutical, Co., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
2. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
3. Tianyin Pharmaceutical Appoints Three New Independent Board Members
4. Tianyin Pharmaceutical Announces SFDA Approval to Market Azithromycin Dispersible Tablets
5. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
6. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
(Date:11/24/2015)... LAVAL, QC , Nov. 24, 2015 /CNW Telbec/ - ... the "Corporation") announced today that Mr. Pierre Laurin , ... a corporate presentation at the upcoming Piper Jaffray 27 th ... York Palace Hotel, on December 1-2, 2015. ... be available for one-on-one meetings throughout the day. The presentation ...
(Date:11/24/2015)... NEW YORK , November 24, 2015 /PRNewswire/ ... Bristol-Myers Squibb in a European ... Company in which the companies will work closely together ... other areas of unmet medical need. The collaboration is underpinned ... the latest LSP fund. This is the first investment by ...
(Date:11/23/2015)... Ceres, Inc . (Nasdaq: CERE ), an agricultural ... year ended August 31, 2015 and provided an update ... --> During fiscal year 2015, Ceres refocused its ... better balance of yield, energy and nutrition. Among other ... crop input providers and made significant progress in advancing ...
(Date:11/23/2015)... , November 23, 2015 The ... to develop daclatasvir for 112 ...   --> --> The ... a hepatitis C medicine, signing an agreement with Bristol-Myers Squibb ... help cure multiple genotypes of the HCV virus.  The royalty-free ...
Breaking Biology Technology:
(Date:10/26/2015)... , Oct. 26, 2015  Delta ID Inc., a ... to mobile and PC devices, announced its ActiveIRIS® technology ... arrows NX F-02H launched by NTT DOCOMO, INC in ... is the second smartphone to include iris recognition technology, ... ARROWS NX F-04G in May 2015, world,s first smartphone ...
(Date:10/23/2015)... GOLETA, California , October 23, 2015 ... and SensoMotoric Instruments (SMI) announce a mobile plug and ... captured during interactive real-world tasks SensoMotoric Instruments ... of their established wearable solutions for eye tracking and ... behavior captured with SMI Eye Tracking Glasses 2w ...
(Date:10/22/2015)... Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a leading ... first quarter ended September 30, 2015. --> ... fiscal 2016 grew 66 percent over the comparable quarter last year ... 2016 was $23.8 million, or $0.62 per diluted share. ... the first quarter of fiscal 2016 grew 39 percent over the ...
Breaking Biology News(10 mins):